ArticleJournal of natural medicines2026
Processed phellodendri Chinensis cortex attenuates diabetic nephropathy via ferroptosis inhibition through GPX4/SLC7A11/Nrf2/HO-1 signaling pathway.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetic nephropathy (DN) is a common complication of diabetes, increasingly linked to ferroptosis as an important underlying mechanism. While Phellodendri chinensis Cortex (PC) has shown renoprotective promise, the therapeutic value of its processed products remains unclear. We therefore compared raw PC (RPC) with three processed derivatives—salt-processed PC (SPC), salt praeparatum-processed PC (SP-PC), and depositum urinae praeparatum-processed PC (DUP-PC)—to evaluate whether processing enhances anti-ferroptotic activity and DN protection. UPLC-Q-TOF-MS profiling identified 51 chemical constituents, dominated by alkaloids in positive-ion mode and phenolic acids in negative-ion mode. In high-glucose-challenged HK-2 cells, SP-PC and SPC significantly outperformed RPC, demonstrating markedly enhanced inhibition of ferroptosis by lowering malondialdehyde (MDA), Fe²⁺, and reactive oxygen species (ROS) while restoring glutathione (GSH) and up-regulating key pathway components GPX4, SLC7A11, Nrf2, and HO-1. These findings were mirrored in streptozotocin (STZ)-plus-high-fat-diet DN rats, where SP-PC and SPC more effectively reduced serum creatinine (S-Cr), blood urea nitrogen (BUN), microalbumin-to-albumin ratio (MAU/ALB) and attenuated renal ferroptosis markers. Critically, both cellular and animal experiments consistently revealed that processing significantly enhances the anti-ferroptotic activity of PC. Thus, processed PC products—especially SP-PC and SPC—confer superior protection against DN by more effectively inhibiting ferroptosis via the GPX4/SLC7A11/Nrf2/HO-1 axis, highlighting processing as a key strategy to boost anti-ferroptotic efficacy in renal protection.
Indexed as
Identifiers
42014593What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.